NIH published a formal Federal Register notice on November 17, 2026, documenting a reorganization of the National Institute of Allergy and Infectious Diseases that abolishes its Division of Clinical Research and redistributes functions. The notice assigns clinical oversight, regulatory operations and biostatistics responsibilities across a revised structure, giving researchers and institutional partners a new map of the offices responsible for those functions.
Formal notice sets out the revised organization
The Statement of Organization, Functions, and Delegations of Authority says NIAID has modified its organizational structure. Published as document 2026-23394 on pages 73762–73764, it amends the Department of Health and Human Services organizational statement. The document was filed on November 16 at 8:45 a.m.
The changes include retitling the Office of the Chief of Staff for the Immediate Office of the Director as the Office of the Clinical Director, or OCD, and establishing two units within it. An Office of Biostatistics Research and two branches are established at institute level. Two other units are established within the Division of Intramural Research, or DIR. The notice removes the Division of Clinical Research and its listed constituent offices, branches and sections from the organizational statement.
This formal organizational action follows a separate leadership announcement: NIH named John H. Powers III director on November 16, as covered in CASRAI’s report on the appointment. The new notice supplies functional assignments for the revised organization.
Clinical oversight combines broad policy with intramural operations
The Office of the Clinical Director develops and evaluates human-subjects research policies within NIAID and advises its director on the clinical research portfolio. Its protocol-review remit includes mission relevance, public-health priority, research ethics and scientific design. It also oversees study design and conduct in collaboration with intramural and extramural programs.
Several operational responsibilities have a specifically intramural scope. These include oversight of clinical research conducted by intramural laboratories, regulatory surveillance of intramural trials, and support for intramural safety monitoring. The distinction matters: the functional statement combines institute-level policy and collaboration with defined responsibilities for NIAID’s own clinical research operations.
Within OCD, the Intramural Clinical Management and Operations Branch oversees clinical operations for intramural laboratories. Its responsibilities include inpatient units and outpatient clinics in conjunction with the NIH Clinical Center, clinical protocol review and approval, care quality for the intramural patient population, continuing medical education and graduate physician training. For collaborators developing a clinical trial protocol, the notice identifies where those intramural review and management responsibilities sit.
Regulatory office has defined sponsor and safety duties
The Office of Clinical Research Policy and Regulatory Operations, also within OCD, provides protocol-development support and coordinates logistical services for clinical research projects. It maintains regulatory surveillance over DIR-supported trials and coordinates policies across NIAID divisions on behalf of the institute’s Clinical Research Subcommittee.
Its stated duties include developing, maintaining and submitting investigational new drug applications to the Food and Drug Administration, authorizing trial sites, reviewing adverse-experience reports for DIR-sponsored trials and preparing safety and IND reports. It must ensure sponsor responsibilities for IND and investigational device exemption applications held by the office are fulfilled or appropriately documented when transferred.
The office also supports the intramural Data and Safety Monitoring Board, safety-monitoring committees and independent medical monitors. Other functions include liaison with FDA and review of regulatory components of DIR clinical trial agreements and Cooperative Research and Development Agreements. These assignments connect protocol support, sponsor obligations and safety reporting within one office.
Biostatistics receives an institute-wide role
The Office of Biostatistics Research is assigned institute-wide leadership and strategic support. Its functions include advising on statistical rigor, reproducibility, data integrity and analytic accuracy, coordinating Data and Safety Monitoring Boards, and supporting transparent communication of research results.
Its Biostatistics Research Branch collaborates with intramural and extramural investigators on clinical, population-based and laboratory studies. The branch provides statistical leadership for safety monitoring and protocol review, conducts independent research on statistical methods, and supports biostatisticians and early-career investigators.
The Clinical Trials Research and Statistics Branch serves as a central resource for high-priority infectious-disease trials, combining trial design, statistical methods, data management and operations. The notice describes an operational hub for special initiatives and rapid-response missions, including a ready-to-use trial capability during outbreaks or urgent research responses. This institute-level remit is distinct from the intramural clinical-management responsibilities placed under OCD.
Frederick units established within intramural research
Within DIR, the notice establishes the Laboratory of Viral Zoonoses and the IRF-Frederick Comparative Medicine Branch. The laboratory’s described activities include research on emerging and re-emerging zoonotic infections, evaluation of medical countermeasures and training associated with high-containment research. The comparative medicine branch provides centralized animal care, research support, training and animal-welfare compliance functions at the Integrated Research Facility-Frederick.
The organizational statement thus specifies destinations for scientific and support functions alongside clinical oversight and statistics. CASRAI’s reading is that research partners should distinguish each unit’s assigned purpose when identifying an institutional counterpart.
September consultation drew concerns about coordination
The earlier public-hearing notice sought comments from September 14 through September 18 on abolishing the Division of Clinical Research and realigning clinical operations and oversight across NIAID components.
In its September 18 response, the Global Health Technologies Coalition warned that redistributing the division’s functions could fragment expertise and weaken coordination between domestic and international research. It urged transparency, consistent clinical oversight and continuity for research partners. Those comments concerned the proposal and described risks of restructuring.
The Infectious Diseases Society of America’s September 18 comments called for an external review, publication of its findings, detailed explanations of proposed changes, stakeholder engagement and a 90-day written-comment opportunity. IDSA also argued that scientific autonomy and clinical expertise should guide grantmaking. These were recommendations during the earlier consultation.
Research offices can map responsibilities by function
For research administrators, the practical implication is to separate intramural clinical operations, institute-wide statistical support and the regulatory responsibilities attached to particular office-held applications. That is CASRAI’s interpretation of the published assignments. The relevant contact depends on the function and research relationship involved.
The revised statement gives offices a basis for checking which NIAID component is responsible for protocol support, safety-monitoring coordination, statistical collaboration or regulatory agreements. Its concrete next step is organizational: those named units have the functions described in the notice. Institutions can use that allocation when reviewing their existing collaboration and oversight arrangements.
Sources
- NIH / Federal Register: Statement of Organization, Functions, and Delegations of Authority, document 2026-23394, November 17, 2026. Checked 2026-11-17.
- NIH / Federal Register: Notice of Public Hearing: NIAID Proposed Reorganization, August 31, 2026. Checked 2026-11-17.
- Global Health Technologies Coalition: GHTC responds to RFI on reorganization of NIAID, September 18, 2026. Checked 2026-11-17.
- IDSA: Comments from the Infectious Diseases Society of America on Proposed NIAID Reorganization, September 18, 2026. Checked 2026-11-17.
- NIH: Dr. John H. Powers III to serve as director of NIH’s National Institute of Allergy and Infectious Diseases, November 16, 2026. Checked 2026-11-17.







